[{"id":"ac22c3c9-66ab-4000-be70-b84ca8b1533a","acronym":"BGB-LC-201","url":"https://clinicaltrials.gov/study/NCT05635708","created_at":"2022-12-02T15:56:38.256Z","updated_at":"2025-02-25T16:18:24.125Z","phase":"Phase 2","brief_title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05635708 - BGB-LC-201","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"}]